Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
Share Fallers
Why Dexus, Mayne Pharma, Nufarm, and Treasury Wine shares are falling today
Share Fallers
Why James Hardie, Mayne Pharma, Nufarm, and Resimac shares are falling today
Mergers & Acquisitions
This ASX 300 share is sinking 33% on takeover collapse fears
Share Gainers
Why Domain, Mayne Pharma, QBE, and Telix shares are jumping today
Healthcare Shares
Can you guess which ASX 300 healthcare stock is rocketing 34% on takeover news
Healthcare Shares
Guess which ASX 300 healthcare stock just rocketed 20% on BIG earnings growth
Share Gainers
Why Ansell, GQG, Mayne Pharma, and Star shares are charging higher today
Share Gainers
Why Bank of Queensland, Fisher & Paykel, Mayne Pharma, and Medibank shares are rising
Earnings Results
3 ASX healthcare stocks surging after strong FY24 earnings
Share Fallers
Why Lovisa, Mayne Pharma, Pilbara Minerals, and RPMGlobal shares are falling today
Share Gainers
Why Appen, Mayne Pharma, Playside, and PYC shares are storming higher
Broker Notes
3 ASX 300 shares receiving broker upgrades today (one with 25% potential upside)
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
